NCT01756482View on ClinicalTrials.gov

Safety and Efficacy Study of GS-5806 in Healthy Volunteers Infected With Respiratory Syncytial Virus (RSV)

PHASE2CompletedINTERVENTIONAL

Enrollment

140

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions

Respiratory Syncytial Virus Infections

Interventions

DRUG

GS-5806

GS-5806, powder for oral solution

DRUG

Placebo

Trial Locations (1)

E12AX

Retroscreen Virology, London

Sponsors

Lead Sponsor

Gilead Sciences

All Listed Sponsors

lead

Gilead Sciences

INDUSTRY

NCT01756482 - Safety and Efficacy Study of GS-5806 in Healthy Volunteers Infected With Respiratory Syncytial Virus (RSV) | Biotech Hunter | Biotech Hunter